AB Science 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Alain Moussy

최고 경영자

€629.0k

총 보상

CEO 급여 비율	51.0%
CEO 임기	23.3yrs
CEO 소유권	24.4%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	3.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Alain Moussy 의 보수는 AB Science 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-€6m
Mar 31 2024	n/a	n/a	-€9m
Dec 31 2023	€629k	€321k	-€12m
Sep 30 2023	n/a	n/a	-€14m
Jun 30 2023	n/a	n/a	-€17m
Mar 31 2023	n/a	n/a	-€15m
Dec 31 2022	€622k	€321k	-€14m
Sep 30 2022	n/a	n/a	-€15m
Jun 30 2022	n/a	n/a	-€17m
Mar 31 2022	n/a	n/a	-€16m
Dec 31 2021	€622k	€622k	-€14m
Sep 30 2021	n/a	n/a	-€13m
Jun 30 2021	n/a	n/a	-€11m
Mar 31 2021	n/a	n/a	-€13m
Dec 31 2020	€625k	€622k	-€15m
Sep 30 2020	n/a	n/a	-€16m
Jun 30 2020	n/a	n/a	-€18m
Mar 31 2020	n/a	n/a	-€20m
Dec 31 2019	€405k	€405k	-€22m
Sep 30 2019	n/a	n/a	-€25m
Jun 30 2019	n/a	n/a	-€28m
Mar 31 2019	n/a	n/a	-€27m
Dec 31 2018	€482k	€482k	-€26m
Sep 30 2018	n/a	n/a	-€25m
Jun 30 2018	n/a	n/a	-€25m
Mar 31 2018	n/a	n/a	-€26m
Dec 31 2017	€415k	€261k	-€27m

보상 대 시장: Alain 의 총 보상 ($USD 658.98K )은 German 시장( $USD 474.54K ).

보상과 수익: 회사가 수익성이 없는 동안 Alain 의 보상이 증가했습니다.

CEO

Alain Moussy

23.3yrs

테뉴어

€629,000

보상

Mr. Alain Moussy, MBA is a Co-Founder of AB Science S.A. and has been its Chief Executive Officer since July 2001 and Managing Director. Mr. Moussy serves as Chairman since July 11, 2001 and serves as its...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Alain Moussy	Co-Founder	23.3yrs	€629.00k	24.42% € 12.3m
Patrick Moussy	Director	23.3yrs	데이터 없음	데이터 없음
Cecile Guillebon	Independent Director	3.4yrs	데이터 없음	데이터 없음
Catherine Johnston-Roussillon	Independent Director	3.4yrs	데이터 없음	데이터 없음
Guillemette Latscha	Independent Director	3.4yrs	데이터 없음	데이터 없음
Renaud Sassi	Independent Director	3.4yrs	데이터 없음	데이터 없음

3.4yrs

평균 재임 기간

경험이 풍부한 이사회: A8D 의 이사회는 경험(평균 재직 기간 3.4 년)으로 간주됩니다.

AB Science 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Insufficient new directors

AB Science S.A., Annual General Meeting, Jun 26, 2024

AB Science Announces Changes in the Board of Directors

Recent updates

AB Science Receives Notice of Allowance for European Patent Covering Masitinib Until 2040 in the Treatment of Sickle Cell Disease

First half 2024 earnings released: €0.09 loss per share (vs €0.22 loss in 1H 2023)

AB Science Announces Positive Results of Its Phase 2 Study Evaluating Masitinib in Covid-19

Insufficient new directors

New minor risk - Market cap size

AB Science S.A., Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released

New minor risk - Financial data availability

AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS

AB Science S.A. to Report First Half, 2024 Results on Sep 30, 2024

AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosis

First half 2023 earnings released: €0.22 loss per share (vs €0.15 loss in 1H 2022)

New minor risk - Financial data availability

New minor risk - Financial data availability

New minor risk - Shareholder dilution

AB Science S.A. Receives Notice of Allowance for European Patent Covering Masitinib in the Treatment of Metastatic Castrate Refractory Prostate Cancer (mCRPC)

Full year 2022 earnings released: €0.29 loss per share (vs €0.30 loss in FY 2021)

AB Science S.A. to Report Fiscal Year 2022 Results on Apr 28, 2023

AB Science S.A. Receives Approval from the U.S. Food and Drug Administration (FDA) to Initiate the Confirmatory Phase 3 Study with Masitinib in the Treatment of Progressive Multiple Sclerosis

AB Science S.A. announced that it expects to receive €15 million in funding from European Investment Bank, Investment Arm

AB Science SA Receives Notice of Deficiency from Health Canada for Masitinib in Treatment of Amyotrophic Lateral Sclerosis

AB Science SA Receives U.S. Food and Drug Administration Authorization to Initiate Confirmatory Phase 3 Clinical Study with Masitinib in the Treatment of Alzheimer’s Disease

AB Science Sa Receives First Agencies Authorizations to Initiate Confirmatory Phase 3 Clinical Study with Masitinib in the Treatment of Alzheimer's Disease

First half 2022 earnings released: EPS: €0 (vs €0.099 loss in 1H 2021)

AB Science SA Announces Positive Recommendation of Data and Safety Monitoring Board to Continue Phase 2 Study Evaluating Antiviral Activity of Masitinib in Covid-19

AB Science Announces That It Has Filed an Application for Conditional Marketing Authorization to EMA for Masitinib in the Treatment of ALS

AB Science SA Announces Publication of Results from its Positive Study of Masitinib in Severe Asthma Uncontrolled by Oral Corticosteroids in the Peer-Reviewed Journal of Asthma and Allergy

AB Science Announces Changes in the Board of Directors

AB Science S.A. Announces Publication of Results from Its Positive Pivotal Phase 3 Trial of Masitinib in Progressive Forms of Multiple Sclerosis in the Peer-Reviewed Journal Neurology® Neuroimmunology & Neuroinflammation

AB Science SA Announces Health Canada Has Granted Authorization to File New Drug Submission for Masitinib in the Treatment of ALS Under the Notice of Compliance with Conditions (NOC/c) Policy

AB Science SA Grants Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the Swedish Medical Products Agency

AB Science SA Receives Authorization to Initiate Phase II Study in Patients with Severe Mast Cell Activation Syndrome by the French Health Authority (ANSM)

AB Science Announces That It Has Been Granted Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the French Health Authority (ANSM)

AB Science S.A. Announces Dosing of First Patient in Phase 2 Trial of Masitinib’s Antiviral Activity Against the SARS-CoV-2 (Covid-19) Virus

AB Science Receives FDA Authorization to Initiate Phase 1/Ii Trial of Ab8939 in the Treatment of Acute Myeloid Leukemia

First half 2021 earnings released: €0.099 loss per share (vs €0.23 loss in 1H 2020)

AB Science SA Receives Regulatory Authorization to Commence A Second Phase 2 Covid-19 Study

AB Science S.A. Receives Health Canada Approval Letter to Commence Phase I/II Trial of Ab8939 in the Treatment of Acute Myeloid Leukemia (AML)

AB Science S.A. Receives Authorization to Resume Patient Enrollment in the Phase 2 Masitinib Study of Covid-19

AB Science S.A. Receives New Authorizations to Resume Patient Enrollment in Its Phase 3 Studies of Masitinib

AB Science Announces Results from Masitinib Study Ab12003 in Prostate Cancer Have Been Presented At the 2021 American Urological Association

AB Science SA Announces That It Has Received Second Authorization to Resume Patient Enrollment, in the Phase 3 Study of Masitinib in Mastocytosis

AB Science Announces Receives the First Authorization to Resume Patient Enrollment in the Confirmatory Phase 3 Study of Masitinib (AB19001) in ALS

AB Science Announces the Validation of Its Risk Management Plan by the French National Agency (ANSM) in Order to Restart Patient Enrollment in France

AB Science SA Announces Results from Masitinib Study AB12005 in Pancreatic Cancer Have Been Presented At the 2021 Asco Annual Meeting

AB Science SA Announces Update of Masitinib

AB Science SA Communicates Results from Phase 3 Study Evaluating Masitinib in Prostate Cancer

AB Science Sa Announces Results from Masitinib Study AB12005 in Pancreatic Cancer, Have Been Selected for Presentation at the Upcoming Asco Annual Meeting

Full year 2020 earnings released

AB Science Sa Announces Identification of Two Tissue Biomarkers That Could Potentially Serve as Predictive Biomarkers of Response for Masitinib Treatment

AB Science Announces a New Independent Publication Confirms That Masitinib Has Anti-Vital Activity Against the SARS-CoV-2 Virus in Vitro and Is A Promising Candidate for Treating COVID-19

AB Science S.A. has completed a Follow-on Equity Offering in the amount of €10.50001 million.

AB Science Issues A Corrective Press Release Regarding Adverse Events Information from Study AB09004 Reported on December 16, 2020

AB Science Announces That Phase 2B/3 Study Evaluating Oral in Alzheimer’S Disease Met Its Primary Endpoint

New 90-day high: €14.44

AB Science S.A. Announces That Confirmatory Phase 3 Study AB12005 with Masitinib in First Line Pancreatic Cancer with Pain Was Successful

AB Science S.A. Announces Results from masitinib Study AB07015 in Severe Asthma Have Been Selected for Presentation At an ATS Symposium Held on October 16, 2020

First half earnings released

AB Science SA Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Large Multiple Sclerosis Research Conference

New 90-day high - €13.28

New 90-day high - €10.12

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간